ReviewPharmacology of antidepressants
Section snippets
DIAGNOSIS OF DEPRESSION AND ITS PREVALENCE
Despite extensive research to find a diagnostic test, the diagnosis of depression remains clinical. The criteria for the diagnosis of major depression5 are the core signs and symptoms, including depressed mood, diminished pleasure or interest in activities, pronounced change in appetite or weight, alterations in sleep (insomnia or hypersomnia), psychomotor agitation or retardation, fatigue or loss of energy, inability to concentrate, indecisiveness, and thoughts of death, dying, or suicide.
A
PHARMACOTHERAPY FOR DEPRESSION
Antidepressant drugs are the mainstay for the treatment of depression. Usually, antidepressants are given in combination with some form of limited supportive psychotherapy. For mild depression, psychotherapy alone may be of use. However, evidence is accumulating that the combination of antidepressant treatment and some form of psychotherapy may be superior to either treatment alone, especially for more severe and recurrent depression.25, 26, 27
Over the past decade, the so-called tricyclic
CLASSIFICATION OF AVAILABLE ANTIDEPRESSANTS
When fewer antidepressant compounds were available, the drugs were classified either as tricyclic antidepressants or as monoamine oxidase inhibitors (MAOIs), a classification that mixes a structural criterion with a functional one. At present, a broad range of structures make up the antidepressant pharmacopoeia, but there are only a few known functional (possibly therapeutic) effects of these compounds. Therefore, a functional classification of antidepressants is more useful than a structural
Onset of Activity
Practicing clinicians know that the mood-elevating effect of antidepressant medication usually begins about 1 to 2 weeks after initiation of treatment. The clinical rule of thumb is that a patient must be treated with an adequate dosage for at least 6 weeks before the clinician considers changing the treatment. However, the synaptic effects of these drugs occur within hours after the patient ingests the drug.31 Because many of the early adverse effects have the same time course as the early
CONCLUSION: THE FUTURE, PAST, AND PRESENT
What might the future bring with respect to the pharmacological treatment of depression in the United States? Compounds that block transporters are still under development. For example, reboxetine, a compound selective for the norepinephrine transporter, may be marketed in the United States within the next few years, several years after the marketing of this compound outside the United States. Drugs that potently block more than 1 transporter are also under development. An example of this class
REFERENCES (170)
- et al.
The prevalence, associations and symptoms of depression amongst dementia sufferers
J Affect Disord
(1996) - et al.
Epidemiology of dementia in Rochester, Minnesota
Mayo Clin Proc
(1996) Depression and anxiety secondary to medical illness
Psychiatr Clin North Am
(1990)- et al.
Is the lifetime risk of depression actually increasing?
J Clin Epidemiol
(1995) - et al.
Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis I disorders
Biol Psychiatry
(1996) - et al.
Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients
Kidney Int
(2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability
J Affect Disord
(2000)Pharmacology of antidepressants-characteristics of the ideal drug
Mayo Clin Proc
(1994)- et al.
A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
J Affect Disord
(1999) Pharmacokinetic drug interactions of new antide-pressants: a review of the effects on the metabolism of other drugs
Mayo Clin Proc
(1997)
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Biochem Pharmacol
Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms
Biol Psychiatry
Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers
Neuropharmacology
Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects
Psychiatry Res
A serotonergic innervation of noradrenergic neurons in nucleus locus coeruleus: demonstration by immunocytochemical localization of the transmitter specific enzymes tyrosine and tryptophan hydroxylase
Brain Res
Noradrenergic innervation of serotonergic neurons in the dorsal raphe: demonstration by electron microscopic autoradiography
Brain Res
Structural characterization and binding sites of G-protein-coupled receptors
Drug Discov Today
The question of feedback at the somadendritic region and antidepressant drug action
Brain Res Bull
Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists
Trends Neurosci
The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial
Biol Psychiatry
Beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: implications for antidepressant therapy
Neuropsychopharmacology
Serotonin type-1A receptor imaging in depression
Nucl Med Biol
The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine
Biol Psychiatry
The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services
Arch Gen Psychiatry
Prevalence of mental illness in Germany and the United States: comparison of the Upper Bavarian Study and the Epidemiologic Catchment Area Program
J Nerv Ment Dis
The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression
JAMA
The treatment of depressive states with G 22355 (imipramine hydrochloride)
Am J Psychiatry
Diagnostic and Statistical Manual of Mental Disorders
Comorbidity of gastrointestinal complaints, depression, and anxiety in the Epidemiologic Catchment Area (ECA) Study
Am J Med
Increasing rates of depression
JAMA
Clinical epidemiology of suicide
J Clin Psychiatry
Suicide mortality among patients treated for depression in an insured population
Am J Epidemiol
Down-rating lifetime suicide risk in major depression
Acta Psychiatr Scand
Depression following myocardial infarction: impact on 6-month survival [published correction appears in JAMA. 1994;271:1082]
JAMA
Depression is a risk factor for coronary artery disease in men: the precursors study
Arch Intern Med
The economic burden of depression in 1990
J Clin Psychiatry
Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization
Arch Gen Psychiatry
The NIMH Depression Awareness, Recognition, and Treatment Program: structure, aims, and scientific basis
Am J Psychiatry
Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects
Arch Gen Psychiatry
Are SSRIs better than TCAs? comparison of SSRIs and TCAs: a meta-analysis
Depress Anxiety
Electroconvulsive Therapy
Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations
Arch Gen Psychiatry
Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years
JAMA
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression
N Engl J Med
Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors
Acta Psychiatr Scand Suppl
Just what is a heterocyclic antidepressant? [letter]
J Clin Psychiatry
Evidence of the dual mechanisms of action of venlafaxine
Arch Gen Psychiatry
Rapid onset of action of venlafaxine
Int Clin Psychopharmacol
Mirtazapine and the onset of antidepressant action: survival function analysis-response [abstract]
Eur Neuropsychopharmacol
Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs: meta-regression analysis
Br J Psychiatry
Cited by (194)
The food preservative sodium propionate induces hyperglycaemic state and neurological disorder in zebrafish
2022, Neurotoxicology and TeratologyQualitative and semi-quantitative screening of selected psychoactive drugs in blood: Usefulness of liquid chromatography – triple quadrupole and quadrupole time-of-flight mass spectrometry in routine toxicological analyses
2022, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesMethods and considerations for the use of hormonal contraceptives in rat models of neurobehavior
2022, Frontiers in NeuroendocrinologyBiomarkers for Deep Brain Stimulation in Animal Models of Depression
2022, NeuromodulationTricyclic antidepressants for treatment-resistant depression
2022, Managing Treatment-Resistant Depression: Road to Novel TherapeuticsDepressive symptoms in rehabilitation post-spinal cord injury
2022, Cellular, Molecular, Physiological, and Behavioral Aspects of Spinal Cord Injury
In the recent past, I have given lectures sponsored by GlaxoSmithKline, Janssen Pharmaceutica, Organon, and Pfizer. Also, I received a grant from Pharmacia.